Alopexx (ALPX) IPO deck
Alopexx is a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal, and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG).
This post is for subscribers only
SubscribeAlready have an account? Log in
%20IPO%20deck){kind=link}